Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
View original at globenewswire.comGalera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Combined company to operate as Obsidian Therapeutics, Inc…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Obsidian's pipeline and OBX-115 offer near-term, value creating milestones for Galera stockholders
60% confidenceOBX-115 offers an opportunity to provide patients with an improved TIL product and patient experience
60% confidenceCombined company's cash balance at closing is anticipated to fund operations into the second half of 2028
60% confidenceTopline data from melanoma registration-enabling trial expected by year-end 2027
60% confidencePhase 1 data from the ongoing NSCLC trial expected in the first half of 2027
60% confidenceThe transaction with Obsidian is the best path forward for Galera
60% confidenceThe transaction and support from leading life sciences investors will allow Obsidian to advance development plans for OBX-115 in melanoma and NSCLC
60% confidenceAt Obsidian, they are striving to deliver a best-in-class TIL cell therapy developed using their proprietary protein-regulation technology
60% confidence